
GT Biopharma, Inc. — Investor Relations & Filings
GT Biopharma, Inc. is a clinical-stage immuno-oncology company focused on developing innovative therapies based on its proprietary NK cell engager (TriKE®) technology. The TriKE® platform generates therapeutic agents that are designed to simultaneously bind to Natural Killer (NK) cells and cancer cells. This targeted engagement activates and directs the cytotoxic function of NK cells to selectively destroy malignant cells. The company's pipeline targets a range of hematologic malignancies and solid tumors, including acute myeloid leukemia, myeloid dysplastic syndrome, and non-Hodgkin's lymphoma.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K | 2026-05-22 | English | |
| 10-Q | 2026-05-15 | English | |
| Regulatory Filings 2026 | 2026-05-14 | English | |
| 424B3 - GT Biopharma, Inc. (0000109657) (Filer) | 2026-05-13 | English | |
| S-1 | 2026-04-30 | English | |
| 8-K - GT Biopharma, Inc. (0000109657) (Filer) | 2026-04-07 | English |
Browse filings by year
32 years- 2026 14 filings
- 2025 53 filings
- 2024 30 filings
- 2023 31 filings
- 2022 41 filings
- 2021 50 filings
- 2020 42 filings
- 2019 36 filings
- 2018 43 filings
- 2017 41 filings
- 2016 27 filings
- 2015 17 filings
- 2014 8 filings
- 2013 2 filings
- 2012 13 filings
- 2011 32 filings
- 2010 23 filings
- 2009 13 filings
- 2008 20 filings
- 2007 42 filings
- 2006 65 filings
- 2005 49 filings
- 2004 42 filings
- 2003 31 filings
- 2002 12 filings
- 2001 7 filings
- 2000 11 filings
- 1999 9 filings
- 1998 16 filings
- 1997 9 filings
- 1996 20 filings
- 1995 13 filings
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
14 filings
| |||||
| 46817358 | 8-K | 2026-05-22 | English | ||
| 46353927 | 10-Q | 2026-05-15 | English | ||
| 46004618 | Regulatory Filings 2026 | 2026-05-14 | English | ||
| 45772480 | 424B3 - GT Biopharma, Inc. (0000109657) (Filer) | 2026-05-13 | English | ||
| 46004609 | S-1 | 2026-04-30 | English | ||
| 33703557 | 8-K - GT Biopharma, Inc. (0000109657) (Filer) | 2026-04-07 | English | ||
| 46004710 | 10-Q/A | 2026-03-06 | English | ||
| 46004763 | 10-Q/A | 2026-03-06 | English | ||
| 32879155 | 10-K - GT BIOPHARMA, INC. (0000109657) (Filer) | 2026-03-02 | English | ||
| 32879154 | 8-K - GT BIOPHARMA, INC. (0000109657) (Filer) | 2026-03-02 | English | ||
| 46004764 | Regulatory Filings 2026 | 2026-02-02 | English | ||
| 17484916 | 424B3 Filing | 2026-01-30 | English | ||
| 17484931 | S-1 Filing | 2026-01-21 | English | ||
| 17484908 | 424B3 Filing | 2026-01-08 | English | ||
|
2025
1 filing
| |||||
| 9203930 | Regulatory Filings 2025 | 2025-12-03 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Alpha Tau Medical Ltd.
Clinical-stage oncology firm developing alpha radiation the…
|
DRTS | US | Professional, scientific and te… |
|
Alteogen Inc.
Biopharmaceutical firm developing biologics with proprietar…
|
196170 | KR | Professional, scientific and te… |
|
ALTERITY THERAPEUTICS LIMITED
Clinical-stage developer of disease-modifying therapies for…
|
ATH | AU | Professional, scientific and te… |
|
AlzeCure Pharma
Develops therapies for severe diseases, focusing on Alzheim…
|
ALZCUR | SE | Professional, scientific and te… |
|
AMPLIA THERAPEUTICS LIMITED
Clinical-stage developer of FAK inhibitors for solid tumors…
|
ATX | AU | Professional, scientific and te… |
|
ANAPTYSBIO, INC
Clinical-stage biotech developing immunology therapeutics f…
|
ANAB | US | Professional, scientific and te… |
|
ANATARA LIFESCIENCES LTD
Develops non-antibiotic gastrointestinal health solutions f…
|
ANR | AU | Professional, scientific and te… |
|
AngioLab, Inc.
Develops angiogenesis inhibitors for pharmaceuticals and he…
|
251280 | KR | Professional, scientific and te… |
|
Anhui Wanbang Pharmaceutical Technology Co.,Ltd.
Pharmaceutical CRO specializing in clinical trials, BE stud…
|
301520 | CN | Professional, scientific and te… |
|
Anixa Biosciences Inc
A clinical-stage biotech developing therapies and vaccines …
|
ANIX | US | Professional, scientific and te… |
GT Biopharma, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/35496/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=35496 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=35496 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=35496 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 35496}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for GT Biopharma, Inc. (id: 35496)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.